Pfizer's monthly obesity shot has side-effect profile sim…

Pfizer presented data on its experimental monthly obesity drug, berobenatide, at the American Diabetes Association meeting, indicating a side-effect profile similar to Novo Nordisk's Wegovy. The drug aims to provide a monthly alternative to weekly injections already on the market. The VESPER-3 trial showed a mean nausea rate of 38% and mean vomiting rate of 23%, with most patients experiencing mild side effects. Pfizer's acquisition of Metsera for $10 billion has positioned the drug as central to its obesity strategy, especially after the company had to discontinue two other weight-loss candidates due to safety concerns.

Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv

China International Import Expo in Shanghai

A logo of Pfizer is seen next to its products on display at the company’s booth at the 8th China International Import Expo (CIIE) in Shanghai, China, November 6, 2025.REUTERS/Maxim Shemetov Purchase Licensing Rights, opens new tab

Summary
Companies
Pfizer hopes once-a-month shot can differentiate the drug from rivals
Mean vomiting rate in midstage study was 23%
Compound was acquired in $10 billion Metsera deal last year

NEW YORK, June 6 (Reuters) - Pfizer (PFE.N), opens new tab presented data on Saturday that showed a monthly dose of an experimental obesity drug it acquired through ‌its purchase of Metsera last year had a similar side-effect profile as rival Novo Nordisk's (NOVOb.CO), opens new tab weekly injection Wegovy.

The drugmaker hopes the compound, called berobenatide, can be the first GLP-1 weight-loss drug offered as a monthly shot as the company works to differentiate the compound from blockbuster drugs like Wegovy and Eli Lilly's (LLY.N), opens new tab Zepbound.

In February, Pfizer said the compound showed up to 12.3% weight loss in patients without diabetes in ⁠its mid-stage VESPER-3 trial.

Analysts are looking to the drug's side-effect profile to assess whether it will be commercially viable.

Pfizer executives said most patients experienced few or mild side effects, with gastrointestinal events largely limited to early doses and clustered close to when patients received the shot. The results were presented at the American Diabetes Association meeting in New Orleans.

"Because of the very long half life here, you get a very smooth profile compared to weeklies," Pfizer Chief Internal Medicine Officer Jim List said in an interview. "When you give it monthly ... it's very front-loaded. It does not persist through the month."

List said that researchers did see an increase in adverse ‌events after ⁠patients went from a weekly to a monthly dose in the trial, so the company plans to increase the dose more gradually in its late-stage program.

Pfizer presented data on Saturday showing that the mean nausea rate in all the arms of the VESPER-3 study was around 38% and the mean vomiting rate was about 23.3%.

Last month, JP Morgan analyst Chris Schott ⁠said that investors would be looking for the vomiting rate for the drug in the trial to be "20-25% or lower."

Around 25% of patients on Novo Nordisk's Wegovy vomited during that company's weight-loss trial, while around 44% reported nausea.

The experimental drug sits ⁠at the center of Pfizer’s obesity strategy following its $10 billion acquisition of Metsera last year. That brought the drugmaker a new pipeline of metabolic therapies after it was forced to discontinue two of its own weight-loss drug ⁠candidates due to liver safety concerns.

Pfizer is hoping monthly dosing of berobenatide can differentiate the drug from the weekly injections on the market, arguing that less frequent dosing could improve adherence and be attractive to a different set of patients.

Reporting by Michael Erman; Editing by Caroline Humer and Cynthia Osterman

Our Standards: The Thomson Reuters Trust Principles., opens new tab

X
Facebook
Linkedin
Email
Link

Purchase Licensing Rights

Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trial

Read Next / Editor's Picks